Multifarious Immunotherapeutic Approaches to Cure HIV-1 Infection

Overview

Journal Hum Vaccin Immunother

Specialty Allergy & Immunology

Date 2015 Jun 7

PMID 26048144

Citations 3

Authors

Nesrina Imami

Anna A Herasimtschuk

Affiliations

Soon will be listed here.

Abstract

Immunotherapy in the context of treated HIV-1 infection aims to improve immune responses to achieve better control of the virus. To date, multifaceted immunotherapeutic approaches have been shown to reduce immune activation and increase CD4 T-lymphocyte counts, further to the effects of antiretroviral therapy alone, in addition to improving HIV-1-specific T-cell responses. While sterilizing cure of HIV-1 would involve elimination of all replication-competent virus, a functional cure in which the host has long-lasting control of viral replication may be more feasible. In this commentary, we discuss novel strategies aimed at targeting the latent viral reservoir with cure of HIV-1 infection being the ultimate goal, an achievement that would have considerable impact on worldwide HIV-1 infection.

Citing Articles

Activation of Latent HIV-1 T Cell Reservoirs with a Combination of Innate Immune and Epigenetic Regulators.

Palermo E, Acchioni C, Di Carlo D, Zevini A, Muscolini M, Ferrari M J Virol. 2019; 93(21).

PMID: 31413127 PMC: 6803272. DOI: 10.1128/JVI.01194-19.

Codon optimization and improved delivery/immunization regimen enhance the immune response against wild-type and drug-resistant HIV-1 reverse transcriptase, preserving its Th2-polarity.

Latanova A, Petkov S, Kilpelainen A, Jansons J, Latyshev O, Kuzmenko Y Sci Rep. 2018; 8(1):8078.

PMID: 29799015 PMC: 5967322. DOI: 10.1038/s41598-018-26281-z.

Cytokine cascade and networks among MSM HIV seroconverters: implications for early immunotherapy.

Huang X, Liu X, Meyers K, Liu L, Su B, Wang P Sci Rep. 2016; 6:36234.

PMID: 27830756 PMC: 5103227. DOI: 10.1038/srep36234.

References

Hardy G, Imami N, Sullivan A, Nelson M, Gazzard B, Gotch F . Tetanus vaccination with IL-2 during highly active antiretroviral therapy induces sustained and pronounced specific CD4 T-cell responses. AIDS. 2004; 18(16):2199-202. DOI: 10.1097/00002030-200411050-00014. View

Cillo A, Sobolewski M, Bosch R, Fyne E, Piatak Jr M, Coffin J . Quantification of HIV-1 latency reversal in resting CD4+ T cells from patients on suppressive antiretroviral therapy. Proc Natl Acad Sci U S A. 2014; 111(19):7078-83. PMC: 4024870. DOI: 10.1073/pnas.1402873111. View

Robbins G, Addo M, Troung H, Rathod A, Habeeb K, Davis B . Augmentation of HIV-1-specific T helper cell responses in chronic HIV-1 infection by therapeutic immunization. AIDS. 2003; 17(8):1121-6. DOI: 10.1097/00002030-200305230-00002. View

Brown P, Angel J . Granulocyte-macrophage colony-stimulating factor as an immune-based therapy in HIV infection. J Immune Based Ther Vaccines. 2005; 3(1):3. PMC: 1164429. DOI: 10.1186/1476-8518-3-3. View

Pires A, Pido-Lopez J, Moyle G, Gazzard B, Gotch F, Imami N . Enhanced T-cell maturation, differentiation and function in HIV-1-infected individuals after growth hormone and highly active antiretroviral therapy. Antivir Ther. 2004; 9(1):67-75. View

Napolitano L, Lo J, Gotway M, Mulligan K, Barbour J, Schmidt D . Increased thymic mass and circulating naive CD4 T cells in HIV-1-infected adults treated with growth hormone. AIDS. 2002; 16(8):1103-11. DOI: 10.1097/00002030-200205240-00003. View

Deeks S, Tracy R, Douek D . Systemic effects of inflammation on health during chronic HIV infection. Immunity. 2013; 39(4):633-45. PMC: 4012895. DOI: 10.1016/j.immuni.2013.10.001. View

Bullen C, Laird G, Durand C, Siliciano J, Siliciano R . New ex vivo approaches distinguish effective and ineffective single agents for reversing HIV-1 latency in vivo. Nat Med. 2014; 20(4):425-9. PMC: 3981911. DOI: 10.1038/nm.3489. View

Hansen B, Kolte L, Haugaard S, Dirksen C, Jensen F, Ryder L . Improved thymic index, density and output in HIV-infected patients following low-dose growth hormone therapy: a placebo controlled study. AIDS. 2009; 23(16):2123-31. DOI: 10.1097/QAD.0b013e3283303307. View

10.

Herasimtschuk A, Downey J, Nelson M, Moyle G, Mandalia S, Sikut R . Therapeutic immunisation plus cytokine and hormone therapy improves CD4 T-cell counts, restores anti-HIV-1 responses and reduces immune activation in treated chronic HIV-1 infection. Vaccine. 2014; 32(51):7005-7013. DOI: 10.1016/j.vaccine.2014.09.072. View

11.

Herasimtschuk A, Hansen B, Langkilde A, Moyle G, Andersen O, Imami N . Low-dose growth hormone for 40 weeks induces HIV-1-specific T cell responses in patients on effective combination anti-retroviral therapy. Clin Exp Immunol. 2013; 173(3):444-53. PMC: 3949632. DOI: 10.1111/cei.12141. View

12.

Levy Y, Durier C, Krzysiek R, Rabian C, Capitant C, Lascaux A . Effects of interleukin-2 therapy combined with highly active antiretroviral therapy on immune restoration in HIV-1 infection: a randomized controlled trial. AIDS. 2003; 17(3):343-51. DOI: 10.1097/00002030-200302140-00008. View

13.

Ananworanich J, Dube K, Chomont N . How does the timing of antiretroviral therapy initiation in acute infection affect HIV reservoirs?. Curr Opin HIV AIDS. 2014; 10(1):18-28. PMC: 4271317. DOI: 10.1097/COH.0000000000000122. View

14.

Blattman J, Grayson J, Wherry E, Kaech S, Smith K, Ahmed R . Therapeutic use of IL-2 to enhance antiviral T-cell responses in vivo. Nat Med. 2003; 9(5):540-7. DOI: 10.1038/nm866. View

15.

Pires A, Hardy G, Gazzard B, Gotch F, Imami N . Initiation of antiretroviral therapy during recent HIV-1 infection results in lower residual viral reservoirs. J Acquir Immune Defic Syndr. 2004; 36(3):783-90. DOI: 10.1097/00126334-200407010-00004. View

16.

Valdez H, Mitsuyasu R, Landay A, Sevin A, Chan E, Spritzler J . Interleukin-2 Increases CD4+ lymphocyte numbers but does not enhance responses to immunization: results of A5046s. J Infect Dis. 2003; 187(2):320-5. DOI: 10.1086/346056. View

17.

Toubaji A, Hill S, Terabe M, Qian J, Floyd T, Simpson R . The combination of GM-CSF and IL-2 as local adjuvant shows synergy in enhancing peptide vaccines and provides long term tumor protection. Vaccine. 2007; 25(31):5882-91. DOI: 10.1016/j.vaccine.2007.05.040. View

18.

West E, Jin H, Rasheed A, Penaloza-MacMaster P, Ha S, Tan W . PD-L1 blockade synergizes with IL-2 therapy in reinvigorating exhausted T cells. J Clin Invest. 2013; 123(6):2604-15. PMC: 3668811. DOI: 10.1172/JCI67008. View

19.

Imami N, Westrop S, Grageda N, Herasimtschuk A . Long-Term Non-Progression and Broad HIV-1-Specific Proliferative T-Cell Responses. Front Immunol. 2013; 4:58. PMC: 3585435. DOI: 10.3389/fimmu.2013.00058. View

20.

Cellerai C, Harari A, Stauss H, Yerly S, Geretti A, Carroll A . Early and prolonged antiretroviral therapy is associated with an HIV-1-specific T-cell profile comparable to that of long-term non-progressors. PLoS One. 2011; 6(4):e18164. PMC: 3071718. DOI: 10.1371/journal.pone.0018164. View